Qiagen N V 's (QGEN) Outlook - CSIMarket
CSIMarket
 
Qiagen N v   (NYSE: QGEN)
 



  Qiagen N v Outlook

On February 6 2025 the Qiagen N v provided following guidance

nnQIAGEN N.V. Reports Strong Q4 2024 Results Exceeding Expectationsnn

VENLO, The Netherlands — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has released its financial results for the fourth quarter and the full year of 2024, highlighting robust growth that surpassed earlier projections. For Q4 2024, the company achieved net sales of $521 million, reflecting a 2% increase compared to the same period in 2023. Notably, when taking into account constant exchange rates (CER), sales amounted to $525 million, marking a 3% rise over the previous year and exceeding the company's guidance of at least $520 million in CER sales.

Core sales, which exclude discontinued products like NeuMoDx and Dialunox, showed even more impressive growth, climbing 4% in CER. This sets a positive tone for the company as it heads into the new fiscal year.

Additionally, QIAGEN reported an adjusted operating income margin, which further underscores the company's solid operational performance in a competitive market. The results indicate QIAGEN's strong execution on its strategic priorities and its ability to drive growth across its product lines, paving the way for a promising outlook in 2025 and beyond.,





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.